Why Freenome, Inc.’s (FRNM) Stock Is Down 9.18%
As of Friday, October 30, Freenome, Inc.’s FRNM share price has dipped by 9.18%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen™ CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
Commentary & Analysis
Why Freenome, Inc.’s (FRNM) Stock Is Up 8.76%
As of Tuesday, October 20, Freenome, Inc.’s FRNM share price has surged by 8.76%, which has investors questioning if this is right time to sell.Michael Rose
Why Freenome, Inc.’s (FRNM) Stock Is Up 6.47%
As of Monday, October 19, Freenome, Inc.’s FRNM share price has surged by 6.47%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Freenome, Inc.’s (FRNM) Stock Is Down 5.01%
As of Friday, October 16, Freenome, Inc.’s FRNM share price has dipped by 5.01%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Freenome, Inc.’s (FRNM) Stock Is Up 6.31%
As of Friday, August 28, Freenome, Inc.’s FRNM share price has surged by 6.31%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | FRNM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,340.9 | $226.9 | 50% |
|
| Shares Out (Mil) | 26.7 | 53.4 | 35% |
|
| Institutional Ownership | 82.0% | 92.9% | 50% |
|
| Float (Mil) | 49.8 | 40.7 | 46% |
|
| Beta | 0.48 | 0.95 | 27% |
|
| Avg Daily Volume (000s) | 547 | 469 | 60% |
|
| Price Change (52-week) |
18.3% | 46.6% | 67% |
|
| Growth | FRNM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | FRNM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $35 | $37 | 17% |
|
| Net Income (TTM) (Mil) | ($235) | ($44) | 6% |
|
| EPS (TTM) | ($8.836) | ($1.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($108) | ($33) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $29 | $2 | 65% |
|
| Long-Term Debt (Q1) (Mil) | $300 | $4 | 53% |
|
| Enterprise Value (Q1) (Mil) | $3,291 | $174 | 56% |
|
| Valuation | FRNM | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.17 | na |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | FRNM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (494.8%) | 65.6% | 0% |
|
| Net Margin | (664.6%) | (71.5%) | 1% |
|
| ROA | (118.1%) | (47.1%) | 5% |
|
| ROE | 19.2% | (53.0%) | 78% |
|
| Liabilities to Assets | 106.7% | 29.6% | 95% |
|
| F-Score | 1 | 2 | na |
|
Freenome, Inc. did not pass any screens on 10/30/2026.
